News
AXSM
140.97
+5.23%
7.01
Axsome Therapeutics: Buy Rating Reaffirmed as Strong Execution Narrows Losses; $290 Price Target Unchanged
TipRanks · 1d ago
Weekly Report: what happened at AXSM last week (1102-1106)?
Weekly Report · 1d ago
Axsome Advances Adolescent ADHD Study as Investors Await Solriamfetol Data
TipRanks · 4d ago
Axsome Advances Pediatric ADHD Study as Solriamfetol Trial Recruits
TipRanks · 4d ago
Axsome Advances Solriamfetol Safety Study in Children With ADHD
TipRanks · 4d ago
Axsome Therapeutics Price Target Cut to $272.00/Share From $284.00 by Mizuho
Dow Jones · 6d ago
Axsome Therapeutics Is Maintained at Outperform by Mizuho
Dow Jones · 6d ago
Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272
Benzinga · 6d ago
Axsome Therapeutics price target lowered to $272 from $284 at Mizuho
TipRanks · 6d ago
Axsome Therapeutics Price Target Raised to $249.00/Share From $247.00 by Morgan Stanley
Dow Jones · 11/03 17:30
Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 11/03 17:30
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249
Benzinga · 11/03 17:21
Axsome Therapeutics Is Maintained at Buy by UBS
Dow Jones · 11/03 16:26
Axsome Therapeutics Price Target Cut to $239.00/Share From $256.00 by UBS
Dow Jones · 11/03 16:26
UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239
Benzinga · 11/03 16:16
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 11/03 15:03
Axsome Therapeutics Price Target Cut to $273.00/Share From $295.00 by RBC Capital
Dow Jones · 11/03 15:03
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273
Benzinga · 11/03 14:53
Axsome Therapeutics Price Target Cut to $250.00/Share From $275.00 by Guggenheim
Dow Jones · 11/03 14:47
Axsome Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 11/03 14:47
More
Webull provides a variety of real-time AXSM stock news. You can receive the latest news about Axsome Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AXSM
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.